1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.56%
R&D reduction while AGEN shows 7.72% growth. Joel Greenblatt would examine competitive risk.
-79.23%
G&A reduction while AGEN shows 9.30% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-99.88%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-74.55%
Operating expenses reduction while AGEN shows 9.30% growth. Joel Greenblatt would examine advantage.
-74.55%
Total costs reduction while AGEN shows 7.50% growth. Joel Greenblatt would examine advantage.
-99.95%
Both companies reducing interest expense. Martin Whitman would check industry trends.
609.47%
D&A growth above 1.5x AGEN's 8.56%. Michael Burry would check for excessive investment.
90.56%
EBITDA growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
74.50%
Operating income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
136.63%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
91.74%
Pre-tax income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-502.21%
Both companies reducing tax expense. Martin Whitman would check patterns.
91.74%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
91.71%
EPS growth while AGEN declines. John Neff would investigate advantages.
91.71%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.